BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results

Reuters

Sep 08

Sept 8 (Reuters) - Bioatla Inc BCAB.O:

BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR OZURIFTAMAB VEDOTIN IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) FOLLOWING PRODUCTIVE TYPE B (END OF PHASE 2) MEETING WITH FDA

Source text: ID:nGNX4yj9M3

Further company coverage: BCAB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2565686028"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565686028\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565686028?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565686028","market":"fut","top_or_hot":-1,"title":"BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results</title></head><body><p><span>Sept 8 (Reuters)</span><span> - </span>Bioatla Inc <span>BCAB.O</span>:</p><ul><li><p>BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR OZURIFTAMAB VEDOTIN IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) FOLLOWING PRODUCTIVE TYPE B (END OF PHASE 2) MEETING WITH FDA</p></li></ul><p>Source text: <span>ID:nGNX4yj9M3</span></p><p>Further company coverage: <span>BCAB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results</title></head><body><p><span>Sept 8 (Reuters)</span><span> - </span>Bioatla Inc <span>BCAB.O</span>:</p><ul><li><p>BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR OZURIFTAMAB VEDOTIN IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) FOLLOWING PRODUCTIVE TYPE B (END OF PHASE 2) MEETING WITH FDA</p></li></ul><p>Source text: <span>ID:nGNX4yj9M3</span></p><p>Further company coverage: <span>BCAB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCAB","symbol_name":"BioAtla, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUAG04QQ:1","article_id":"2565686028","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565686028","pubTimestamp":1757332928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 ResultsSept 8 (Reuters) - Bioatla Inc BCAB.O:BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCAB":"BioAtla, Inc.","BK4139":"生物科技"},"translate_title":"简介-BioAtla在2期结果积极后向FDA更新了Ozuriftamab Vedotin治疗OPSCC的计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAB":0.9},"content_text":"BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 ResultsSept 8 (Reuters) - Bioatla Inc BCAB.O:BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR OZURIFTAMAB VEDOTIN IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) FOLLOWING PRODUCTIVE TYPE B (END OF PHASE 2) MEETING WITH FDASource text: ID:nGNX4yj9M3Further company coverage: BCAB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}